Marrow transplantation for CML: The Seattle experience

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Clift, R A ^a   Storb, R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Allografting; BMT; CML; Seattle

Indexed keywords

ANTILEUKEMIC AGENT; BUSULFAN; CYCLOSPORIN A;

AGE; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DONOR; HLA MATCHING; HUMAN; PRIORITY JOURNAL; REMISSION; UNITED STATES; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; SURVIVAL RATE; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; WASHINGTON;

EID: 0030003140     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
2. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
3. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.